TY - JOUR
T1 - Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease
AU - Teramachi, Jumpei
AU - Nagata, Yuki
AU - Mohammad, Khalid
AU - Inagaki, Yuji
AU - Ohata, Yasuhisa
AU - Guise, Theresa
AU - Michou, Laëtitia
AU - Brown, Jacques P.
AU - Windle, Jolene J.
AU - Kurihara, Noriyoshi
AU - Roodman, G. David
N1 - Funding Information:
This work was supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH (R01-AR057308, to G.D. Roodman); the National Cancer Institute (NCI), NIH (5P30CA016059, to J.J. Windle); and the US Department of Defense (W81XWH-12-1-0533, to N. Kurihara). The mice for this research were provided by the VCU Transgenic/Knock-out Mouse Shared Resource.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Paget's disease (PD) is characterized by focal and dramatic bone resorption and formation. Treatments that target osteoclasts (OCLs) block both pagetic bone resorption and formation; therefore, PD offers key insights into mechanisms that couple bone resorption and formation. Here, we evaluated OCLs from 3 patients with PD and determined that measles virus nucleocapsid protein (MVNP) was expressed in 70% of these OCLs. Moreover, transgenic mice with OCL-specific expression of MVNP (MVNP mice) developed PD-like bone lesions that required MVNP-dependent induction of high IL-6 expression levels in OCLs. In contrast, mice harboring a knockin of p62P394L (p62-KI mice), which is the most frequent PD-associated mutation, exhibited increased bone resorption, but not formation. Evaluation of OCLs from MVNP, p62-KI, and WT mice revealed increased IGF1 expression in MVNP-expressing OCLs that resulted from the high IL-6 expression levels in these cells. IL-6, in turn, increased the expression of coupling factors, specifically ephrinB2 on OCLs and EphB4 on osteoblasts (OBs). IGF1 enhanced ephrinB2 expression on OCLs and OB differentiation. Importantly, ephrinB2 and IGF1 levels were increased in MVNP-expressing OCLs from patients with PD and MVNP-transduced human OCLs compared with levels detected in controls. Further, anti-IGF1 or anti-IGF1R blocked Runx2 and osteocalcin upregulation in OBs cocultured with MVNP-expressing OCLs. These results suggest that in PD, MVNP upregulates IL-6 and IGF1 in OCLs to increase ephrinB2-EphB4 coupling and bone formation.
AB - Paget's disease (PD) is characterized by focal and dramatic bone resorption and formation. Treatments that target osteoclasts (OCLs) block both pagetic bone resorption and formation; therefore, PD offers key insights into mechanisms that couple bone resorption and formation. Here, we evaluated OCLs from 3 patients with PD and determined that measles virus nucleocapsid protein (MVNP) was expressed in 70% of these OCLs. Moreover, transgenic mice with OCL-specific expression of MVNP (MVNP mice) developed PD-like bone lesions that required MVNP-dependent induction of high IL-6 expression levels in OCLs. In contrast, mice harboring a knockin of p62P394L (p62-KI mice), which is the most frequent PD-associated mutation, exhibited increased bone resorption, but not formation. Evaluation of OCLs from MVNP, p62-KI, and WT mice revealed increased IGF1 expression in MVNP-expressing OCLs that resulted from the high IL-6 expression levels in these cells. IL-6, in turn, increased the expression of coupling factors, specifically ephrinB2 on OCLs and EphB4 on osteoblasts (OBs). IGF1 enhanced ephrinB2 expression on OCLs and OB differentiation. Importantly, ephrinB2 and IGF1 levels were increased in MVNP-expressing OCLs from patients with PD and MVNP-transduced human OCLs compared with levels detected in controls. Further, anti-IGF1 or anti-IGF1R blocked Runx2 and osteocalcin upregulation in OBs cocultured with MVNP-expressing OCLs. These results suggest that in PD, MVNP upregulates IL-6 and IGF1 in OCLs to increase ephrinB2-EphB4 coupling and bone formation.
UR - http://www.scopus.com/inward/record.url?scp=84959912039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959912039&partnerID=8YFLogxK
U2 - 10.1172/JCI82012
DO - 10.1172/JCI82012
M3 - Article
C2 - 26878170
AN - SCOPUS:84959912039
SN - 0021-9738
VL - 126
SP - 1012
EP - 1022
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 3
ER -